CERTIFICATE OF EXPRESS MAILING DATE OF DEPOSIT JULY 24 2003 EXPRESS MAIL NO. ER 1928973|5US DEPOSITED WITH THIS CORRESPONDENCE (ALONG WITH ANY PAPER REFERRED TO AS BEING ATTACHED OR ENCLOSED) IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450. LORT Schepisi Low Lelepsic 7-24-03 Name Date PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Liu, et al.

Serial No.:

09/806,087 - Case No.: 20330P

Filed:

July 2, 2001

For:

G PROTEIN-COUPLED RECEPTOR

RESEMBLING THE THROMBIN RECEPTOR

Art Unit:

1646

Examiner:

Murphy

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE STATEMENT

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the following statement is being submitted with the computer readable form of the Sequence Listing.

I hereby start that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for Case No. 20330P.

Respectfully submitted,

Vineet Kohli

Reg. No. 37,003

Attorney for Applicant

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3889

Date: 7/24/03

10/a 11.9:5 8/5/8

RECEIVED

JUL 3 1 2003

TECH CENTER 1600/2900

Application No.: 0759187NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

12	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
12	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
A 3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the 'Sequence Listing" as required by 37 C.F.R. 1.821(e).
7.0	Other:
Applic	ant Must Provide:
	initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An j	initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
	atement that the content of the paper and computer readable copies are the same and, where licable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 5(b) or 1.825(d).
For que	estions regarding compliance to these requirements, please contact:
For Rul	es Interpretation, call (703) 308-4216
For Pat	F Submission Help, call (703) 308-4212 entIn software help, call (703) 308-6856
	PI FASE PETIEN A CODY OF THE MOTION

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Allinant com



Address COMMISSIONER FPATENTS AND TRADEMARKS WASHINGTON, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	. ATTORNEY DOCKET NO.
40,141,5			·
1		EXAMI	NER

EXAMINER

ART UNIT PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be whose telephone number is (703) 30